A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study

Author:

Ryang Soree12ORCID,Kim Sang Soo12ORCID,Bae Ji Cheol3ORCID,Han Ji Min3ORCID,Kwon Su Kyoung4,Kim Young Il5ORCID,Nam‐Goong Il Seong5ORCID,Kim Eun Sook5ORCID,Kim Mi‐kyung6ORCID,Lee Chang Won7ORCID,Yoo Soyeon8,Koh Gwanpyo8ORCID,Kwon Min Jeong9ORCID,Park Jeong Hyun9ORCID,Kim In Joo12ORCID

Affiliation:

1. Department of Internal Medicine, Pusan National University Hospital Pusan National University School of Medicine Busan South Korea

2. Biomedical Research Institute Pusan National University Hospital Busan South Korea

3. Department of Internal Medicine, Samsung Changwon Hospital Sungkyunkwan University School of Medicine Changwon South Korea

4. Department of Internal Medicine, Kosin University Gospel Hospital Kosin University College of Medicine Busan South Korea

5. Department of Internal Medicine, Ulsan University Hospital University of Ulsan College of Medicine Ulsan South Korea

6. Department of Internal Medicine, Inje University Haeundae Paik Hospital College of Medicine, Inje University Busan South Korea

7. Department of Internal Medicine Busan St. Mary's Hospital Busan South Korea

8. Department of Internal Medicine, Jeju National University Hospital Jeju National University School of Medicine Jeju South Korea

9. Division of Endocrinology & Metabolism, Department of Internal Medicine, Busan Paik Hospital College of Medicine, Inje University Busan South Korea

Funder

Pusan National University Hospital

Clinical Trial Center, China Medical University Hospital

Pusan National University

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3